James E. Frampton

6.8k total citations · 1 hit paper
166 papers, 5.0k citations indexed

About

James E. Frampton is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James E. Frampton has authored 166 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 25 papers in Molecular Biology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James E. Frampton's work include Lung Cancer Treatments and Mutations (8 papers), Ion channel regulation and function (6 papers) and Migraine and Headache Studies (6 papers). James E. Frampton is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Ion channel regulation and function (6 papers) and Migraine and Headache Studies (6 papers). James E. Frampton collaborates with scholars based in New Zealand, United States and United Kingdom. James E. Frampton's co-authors include Edward S. Chambers, Kevin G. Murphy, Gary Frost, Greg L. Plosker, Clive H. Orchard, Lesley J. Scott, Rachel H. Foster, Mark R. Boyett, Diana Faulds and Monique P Curran and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Physiology.

In The Last Decade

James E. Frampton

165 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function

2020 330 citations James E. Frampton, Kevin G. Murphy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Frampton New Zealand	40	1.3k	699	615	571	532	166	5.0k
Giovanni Ricevuti Italy	37	1.1k 0.9×	932 1.3×	317 0.5×	407 0.7×	611 1.1×	196	4.9k
Yoshinori Itoh Japan	40	1.6k 1.2×	1.0k 1.5×	432 0.7×	241 0.4×	552 1.0×	261	5.7k
Caroline M. Spencer New Zealand	39	1.1k 0.8×	487 0.7×	737 1.2×	307 0.5×	552 1.0×	88	4.7k
Christina Piperi Greece	51	2.8k 2.2×	979 1.4×	647 1.1×	552 1.0×	392 0.7×	257	8.4k
Jacobus Burggraaf Netherlands	43	1.4k 1.1×	868 1.2×	821 1.3×	686 1.2×	932 1.8×	274	6.7k
Katharina Rentsch Switzerland	46	1.4k 1.1×	397 0.6×	699 1.1×	676 1.2×	1.2k 2.3×	186	6.3k
Babak Baban United States	47	2.1k 1.6×	692 1.0×	1.2k 2.0×	329 0.6×	366 0.7×	167	9.0k
Hayder M. Al‐kuraishy Iraq	46	2.1k 1.6×	1.2k 1.8×	406 0.7×	501 0.9×	465 0.9×	369	7.2k
Flávio Reis Portugal	40	1.5k 1.2×	1.1k 1.5×	481 0.8×	392 0.7×	727 1.4×	171	5.6k
Ali I. Al‐Gareeb Iraq	45	2.0k 1.5×	1.2k 1.7×	383 0.6×	475 0.8×	449 0.8×	352	6.9k

Countries citing papers authored by James E. Frampton

Since Specialization

Citations

This map shows the geographic impact of James E. Frampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Frampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Frampton more than expected).

Fields of papers citing papers by James E. Frampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Frampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Frampton. The network helps show where James E. Frampton may publish in the future.

Co-authorship network of co-authors of James E. Frampton

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Frampton. A scholar is included among the top collaborators of James E. Frampton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Frampton. James E. Frampton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Frampton, James E.. (2024). Pemigatinib: A Review in Advanced Cholangiocarcinoma. Targeted Oncology. 19(1). 107–114. 2 indexed citations

2.

Frampton, James E., José Iván Serrano-Contreras, Isabel García‐Pérez, et al.. (2023). The metabolic interplay between dietary carbohydrate and exercise and its role in acute appetite regulation in males: a randomized controlled study. The Journal of Physiology. 601(16). 3461–3480. 5 indexed citations

3.

Frampton, James E.. (2023). Epcoritamab: First Approval. Drugs. 83(14). 1331–1340. 22 indexed citations

4.

Frampton, James E.. (2022). Teserpaturev/G47Δ: First Approval. BioDrugs. 36(5). 667–672. 60 indexed citations

5.

Frampton, James E.. (2022). Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. Targeted Oncology. 17(3). 369–376. 9 indexed citations

6.

Frampton, James E.. (2020). Atezolizumab: A Review in Extensive-Stage SCLC. Drugs. 80(15). 1587–1594. 24 indexed citations

7.

Frampton, James E.. (2020). Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Drugs. 80(7). 729–729. 1 indexed citations

8.

Frampton, James E. & Nicole Basset‐Séguin. (2018). Vismodegib: A Review in Advanced Basal Cell Carcinoma. Drugs. 78(11). 1145–1156. 68 indexed citations

9.

Frampton, James E.. (2017). Pazopanib: a Review in Advanced Renal Cell Carcinoma. Targeted Oncology. 12(4). 543–554. 29 indexed citations

10.

Frampton, James E.. (2016). Sublingual Sufentanil: A Review in Acute Postoperative Pain. Drugs. 76(6). 719–729. 22 indexed citations

11.

Frampton, James E.. (2016). Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs. 76(17). 1675–1682. 72 indexed citations

12.

Keating, Gillian M., Katherine A. Lyseng‐Williamson, & James E. Frampton. (2012). Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer. BioDrugs. 26(6). 431–435. 1 indexed citations

13.

Frampton, James E.. (2010). Tapentadol Immediate Release. Drugs. 70(13). 1719–1743. 27 indexed citations

14.

Frampton, James E.. (2009). Hylan G-F 20 Single-Injection Formulation. Drugs & Aging. 27(1). 77–85. 18 indexed citations

15.

Frampton, James E. & Greg L. Plosker. (2007). Selegiline Transdermal System. Drugs. 67(2). 257–265. 24 indexed citations

16.

Frampton, James E. & Greg L. Plosker. (2007). Duloxetine. CNS Drugs. 21(7). 581–609. 51 indexed citations

17.

Frampton, James E. & Caroline M. Perry. (2005). Emtricitabine. Drugs. 65(10). 1427–1448. 43 indexed citations

18.

Frampton, James E., Simon M. Harrison, Mark R. Boyett, & Clive H. Orchard. (1991). Ca2+ and Na+ in rat myocytes showing different force-frequency relationships. American Journal of Physiology-Cell Physiology. 261(5). C739–C750. 61 indexed citations

19.

Frampton, James E., et al.. (1967). Intrauterine contraceptive devices.. BMJ. 2(5553). 683–687. 4 indexed citations

20.

Frampton, James E., et al.. (1964). Case of intra-amniotic glucose induction followed by nonfatal amniotic fluid embolism and acute renal failure. American Journal of Obstetrics and Gynecology. 90(4). 554–555. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact